Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. The Company is conducting a Phase II clinical trial of Antineoplastons relating to the treatment of cancer. The Company is primarily engaged as a research and development facility of Antineoplaston drugs being tested for use in the treatment of cancer, and provides consulting services. The Company operates primarily as a research and development facility of antineoplaston drugs being tested for the use in the treatment of cancer, and provides consulting services. As of February 28, 2013, the Company had no revenues.